C2N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
C2N Diagnostics Receives $20M Program-Related Investment from GHR Foundation to Bring Alzheimer’s Blood Test to the Clinic
05/14/20, 1:18 PM
Money raised
$20 million
C2N Diagnostics announced today that it has received a $20 million Program-Related Investment from GHR Foundation, an independent global philanthropy. The funds will position C2N’s Alzheimer’s blood test for entry into the clinic. The investment provides resources to build out C2N’s clinical laboratory testing facility in St. Louis, Missouri and to establish a premium quality, patient testing service
Company Info
Additional Info
AccelFoods is an early-stage venture fund investing in consumer products.
We partner with entrepreneurs to bring innovative, high-quality food and
beverage products to the forefront of the industry and create the next
generation of enduring brands. With nearly $40m under management, we are
hands-on partners that work tactically with our founders to scale their
businesses quickly and smartly. We connect the dots within the broader food
& beverage ecosystem to provide unique access, share distinct expertise,
and build solid infrastructure.